Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Melcare Biomedical Pty Ltd
WARNING LETTER
•Melcare Biomedical Pty Ltd•September 10, 2025

Melcare Biomedical Pty Ltd – FDA Warning Letter, Sep 10, 2025

Record Details

The U.S. Food and Drug Administration (FDA) issued a warning letter to Melcare Biomedical Pty Ltd on October 9, 2025, following a review of its product labeling and website on September 10, 2025. The letter addresses significant violations concerning the company"s Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops, which are available for purchase in the United States without a prescription.

The main violations identified are that these products are marketed as unapproved new drugs and are misbranded, contrary to sections 505(a), 301(d), 502(ee), and 301(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA determined that both products are intended as ophthalmic demulcent drug products. However, they fail to conform to the conditions outlined in the Over-the-Counter (OTC) monograph M018 for ophthalmic drug products. Specifically, the products contain honey (from Leptospermum spp.) which is presented as an active ingredient in the labeling. Honey is not a permitted active ingredient for OTC monograph ophthalmic demulcent drug products under M018.12. Consequently, these products cannot be legally marketed under section 505G without an approved new drug application.

The provided excerpt of the warning letter details these violations but does not specify immediate required actions or a response deadline from Melcare Biomedical Pty Ltd.

Company
Melcare Biomedical Pty Ltd
Inspection date
September 10, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Tina Smith (Director)
View Company Profile

ID · 1c5e930f-9f42-4a2f-8ef8-e5a150493c3d

Violation Codes10
FD&C Act 505(a)FD&C Act 301(d)21.U.S.C. 355(a)21 U.S.C. 331(d)FD&C Act 502(ee)21 U.S.C. 352(ee)FD&C Act 301(a)21.U.S.C. 331(a)FD&C Act 201(g)(1)(B)21 U.S.C. 321(g)(1)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Melcare Biomedical Pty Ltd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.